Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-016017
Filing Date
2022-08-09
Accepted
2022-08-09 16:02:22
Documents
65
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q scph-20220630.htm   iXBRL 10-Q 1958842
2 EX-31.1 scph-ex31_1.htm EX-31.1 17448
3 EX-32.1 scph-ex32_1.htm EX-32.1 13522
  Complete submission text file 0000950170-22-016017.txt   7837527

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT scph-20220630_pre.xml EX-101.PRE 294795
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT scph-20220630.xsd EX-101.SCH 45464
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT scph-20220630_def.xml EX-101.DEF 140360
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT scph-20220630_lab.xml EX-101.LAB 408086
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT scph-20220630_cal.xml EX-101.CAL 50398
59 EXTRACTED XBRL INSTANCE DOCUMENT scph-20220630_htm.xml XML 1642180
Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38293 | Film No.: 221148088
SIC: 2834 Pharmaceutical Preparations